As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Medifast, Inc. MED, a prominent player in the health and wellness industry, is making significant strides to expand its ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond ...

Oikos and its other popular brands are seeing a spike in demand as people taking the weight-loss medications turn to the portion-controlled snacks to meet their nutritional needs.